NICE says yes to AstraZeneca’s Fasenra, but only when its GSK rival can’t be used

It hasn’t been an easy couple of months for AstraZeneca when it comes to challenging GlaxoSmithKline’s Nucala (mepolizumab) with newcomer Fasenra (benralizumab). And in England, that ambition just took another hit.